These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8992601)

  • 1. [Indications for bone marrow transplantation].
    Prósper F; Rifón J; Cuesta B; Hermida J; Panizo C; Hernández M; Rocha E
    Rev Med Univ Navarra; 1994; 38(4):212-25. PubMed ID: 8992601
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychosocial morbidity and survival in adult bone marrow transplant recipients--a follow-up study.
    Murphy KC; Jenkins PL; Whittaker JA
    Bone Marrow Transplant; 1996 Jul; 18(1):199-201. PubMed ID: 8832015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting.
    Gustafsson A; Remberger M; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 May; 25(10):1059-65. PubMed ID: 10828866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.
    Dulley FL; Vigorito AC; Aranha FJ; Sturaro D; Ruiz MA; Saboya R; Macedo MC; Da Silva RL; Chamone DA; Mehta J; Bacigalupo A; De Souza CA
    Bone Marrow Transplant; 2004 Jan; 33(1):9-13. PubMed ID: 14578930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
    Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant.
    Bolwell B; Pohlman B; Sobecks R; Andresen S; Brown S; Rybicki L; Wentling V; Kalaycio M
    Bone Marrow Transplant; 2004 Feb; 33(4):419-23. PubMed ID: 14688814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia.
    Viollier R; Passweg J; Gregor M; Favre G; Kühne T; Nissen C; Gratwohl A; Tichelli A
    Ann Hematol; 2005 Jan; 84(1):47-55. PubMed ID: 15340760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone marrow transplantation for severe aplastic anemia].
    Bullorsky EO; Bonduel M; Shanley C; Figueroa C; Stemmelin G; Del Pozo A; Ceresetto J; Delfino S; Puppo M; Muriel FS
    Medicina (B Aires); 1998; 58(2):130-4. PubMed ID: 9706244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful bone marrow transplantation in sensitized aplastic anemia patients using total lymphoid irradiation for conditioning: long-term follow-up.
    Zapatero A; Marín A; López M; Martín De Vidales C; Cerezo L; Domínguez P; Pérez Torrubia A
    Hematol Oncol; 1996 Dec; 14(4):165-72. PubMed ID: 9267462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-year survival after bone marrow transplantation for aplastic anemia.
    Pokorski RJ
    J Insur Med; 1998; 30(4):237-9. PubMed ID: 10537929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.